Valuation : Ipsen

Market Cap 13.37B 15.52B 12.54B 11.45B 21.56B 1,483B 21.63B 149B 58.04B 749B 58.27B 57B 2,483B P/E 2026 *
13.6x
P/E 2027 * 13.9x
Enterprise Value 12.13B 14.08B 11.38B 10.39B 19.57B 1,346B 19.63B 135B 52.67B 679B 52.87B 51.72B 2,253B EV / Sales 2026 *
2.67x
EV / Sales 2027 * 2.39x
Free-Float
40.65%
Yield 2026 *
0.94%
Yield 2027 * 0.94%
1 day-3.05%
1 week-0.09%
Current month-2.18%
1 month+1.96%
3 months+4.17%
6 months-0.94%
Current year+37.78%
1 week 160.4
Extreme 160.4
169.3
1 month 153.1
Extreme 153.1
171.8
Current year 116
Extreme 116
176.6
1 year 109
Extreme 109
176.6
3 years 88.05
Extreme 88.05
176.6
5 years 77.28
Extreme 77.28
176.6
10 years 35.52
Extreme 35.52
176.6
Manager TitleAgeSince
Chief Executive Officer 59 2020-06-30
Chief Executive Officer 57 2019-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 2005-08-29
Chairman 68 2010-11-21
Director/Board Member 69 2012-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.05%-0.09% - - 16.16B
-0.13%-6.44%+60.47%+112.05% 1,048B
+0.85%-0.81%+52.77%+63.15% 640B
-1.03%-3.58%+22.87%+73.29% 456B
-1.46%-4.50%+37.43%+38.41% 362B
-0.72%-2.89%+21.86%+36.79% 295B
-1.19%-2.21%+1.35%+12.29% 255B
-1.05%-1.57%+51.40%+68.55% 236B
+0.08%-1.78%-17.64%-54.29% 204B
-2.14%-0.30%+29.42%+89.10% 185B
Average -0.99%-2.07%+28.88%+48.82% 409.07B
Weighted average by Cap. -0.50%-3.02%+38.56%+65.41%

Financials

2026 *2027 *
Net sales 4.54B 5.27B 4.26B 3.89B 7.33B 504B 7.35B 50.54B 19.72B 254B 19.8B 19.37B 843B 4.64B 5.38B 4.35B 3.97B 7.48B 514B 7.5B 51.58B 20.13B 260B 20.2B 19.76B 861B
Net income 1.01B 1.17B 948M 865M 1.63B 112B 1.63B 11.24B 4.39B 56.59B 4.4B 4.31B 188B 985M 1.14B 924M 843M 1.59B 109B 1.59B 10.96B 4.28B 55.17B 4.29B 4.2B 183B
Net Debt -1.24B -1.44B -1.16B -1.06B -2B -137B -2B -13.77B -5.37B -69.31B -5.39B -5.28B -230B -2.3B -2.67B -2.16B -1.97B -3.71B -255B -3.72B -25.58B -9.98B -129B -10.02B -9.8B -427B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
26-08-28 €169.00 +0.12% 803
26-08-27 €168.80 +1.93% 18,956
26-08-26 €165.60 -0.18% 51
26-08-25 €165.90 +2.53% 119
26-08-24 €161.80 -1.16% 6,997
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
163.10EUR
Average target price
167.07EUR
Spread / Average Target
+2.43%

Quarterly revenue - Rate of surprise